Most positron emission tomography (PET) imaging studies in head and neck cancer are performed using the radiotracer 18-fluorodeoxyglucose ( 18 FDG). PET with FDG has become a standard clinical imaging modality in patients with head and neck cancer. It contributes valuable information in localizing a primary tumor in patients with neck nodal metastases from an unknown primary, in the staging of primary head and neck cancer, and in the detection of recurrent disease. In addition, FDG-PET provides independent prognostic information in patients with newly diagnosed and recurrent head and neck cancer. PET/CT improves lesion localization and accuracy of FDG-PET and is strongly recommended in patients with head and neck cancer. After thyroidectomy, FDG-PET has proven useful in patients with clinical or serological evidence of recurrent or metastatic thyroid carcinoma but negative whole body iodine scan. PET shows metastatic disease in up to 90% of these patients, thereby providing a rational basis for further studies and therapy. In patients with medullary thyroid cancer with elevated calcitonin levels following thyroidectomy, FDG-PET has a sensitivity of 70-75% for localizing metastatic disease. Occasionally incidental intense FDG uptake is observed in the thyroid gland on whole body PET studies performed for other indications. Although diffuse FDG uptake usually indicates thyroiditis, focal uptake has been related to thyroid cancer in 25-50% of cases and should therefore be evaluated further if a proven malignancy would cause a change in patient management.
H
EAD AND NECK SQUAMOUS CELL CARCI-NOMA (HNSCC) is the sixth most common cancer worldwide. In the United States, it accounts for approximately 2% of all cancers and 2% of cancer death. Nevertheless, HNSCC is an important topic in oncologic imaging, because imaging findings can aid significantly in the detection, staging and treatment evaluation of these tumor. Patients presenting with primary tumors that are confined at the time of initial diagnosis (T1/ 2N0M0) have an excellent cure rate. Unfortunately, at the time of initial diagnosis many patients already have regional nodal metastases (45%) or even distant metastases (10%). Also noteworthy is the approximately 5% annual rate of second primaries in HNSCC patients, mostly occurring in the upper aerodigestive tract.
Probably 98% of PET studies in patients with head and neck cancer are performed using FDG as the radiotracer. Consequently, and similar to most other malignancies, our knowledge and experience is largely based on these FDG studies. For the purpose of this practical review we will therefore only discuss FDG-PET, although brief reference will be made to alternate tracers at the end of the text.
Neck Metastases from an Unknown Primary Tumor
This condition, also known as carcinoma of unknown primary, accounts for 3-15% of all cancer diagnoses and for approximately 1-2% of head and neck cancers. For practical purposes, this entity should be defined as the combination of: no history of previous malignancy, no clinical or laboratory evidence for primary neoplasm, neck mass that is histologically or cytologically proven to be carcinoma. Occurrence of nodal metastases in neck levels I-III increases the likelihood for a primary HNSCC. However, in 5-40% of cases a primary malignancy is never identified during diagnostic evaluation and long-term follow-up.
Role of Imaging
Cross-sectional imaging studies (computed tomography [CT] , magnetic resonance imaging [MRI] ) are routinely used in these patients, but oftentimes without providing additional information. PET has been used for the evaluation of patients with unknown primary for a number of years. The number of patients studied exceeds 300 and the percentage of primary tumors detected is quoted from 10 to 60%. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] This wide range of results is largely related to two factors: varying inclusion criteria and methods of verification. In particular the definition of "unknown primary" varies considerably between studies. Categorically speaking, the term unknown primary should only be used after clinical examination, CT/MRI and endoscopy have failed to reveal a primary tumor. Unfortunately, only few studies use such a strict definition. In addition, the sensitivity of PET is oftentimes stated incorrectly: if only lesions that were missed by PET but detected by other means are called as false negative, the resulting sensitivity will be much better than when all negative studies are classified as false negative (by definition, all patients with neck metastasis have a primary tumor somewhere in the body). A summary of larger PET studies in patients with unknown primary is shown in Table 1 , and a patient example in Fig 1 .
Potential reasons for a false-negative PET studies include a small primary tumor (although lesions as small as 4 mm can be detected as long as there is intense FDG uptake); low metabolic activity (cystic, necrotic tumor or lymph nodes); or the primary tumor was accidentally removed at time of neck dissection.
Practical Approach and Take-Home Message
Because of inconsistencies in patient selection and the reporting of results, the question of whether PET should be used at all in this clinical scenario has stirred some controversy. 12 However, we think that PET can be a valuable tool in patients with neck metastases from an unknown primary, provided that patients are appropriately selected. Indeed, we propose that these patients should undergo a thorough head and neck examination by an otorhinolaryngologist or head and neck surgeon, followed by FDG-PET. Other imaging studies rarely contribute valuable information, and it is extremely unlikely that these will identify a primary tumor that cannot be detected by PET. If the PET study is positive, biopsies can be obtained from the suggested location. If the PET is negative, panendoscopy with biopsy sampling from suspected locations (based on the location of the lymph node and statistical considerations) can be performed. Depending on the results of these biopsies, the patient may proceed to surgery or radiation therapy.
Primary Tumor Staging

PET for T-Staging
At the time the patient is referred for staging (imaging) studies, the primary tumor has already been diagnosed, and a clinical head and neck examination has assessed the status of lymph nodes in the neck. The first goal of imaging studies is therefore to determine the extent of the primary tumor, in particular with regard to structures whose involvement may alter the surgical approach (eg, bone invasion, orbital invasion, skull base invasion, tumor "tracking" along nerves and blood vessels). This can be done by either CT or MRI, and PET has little to contribute in this regard. In the few studies that have addressed the ability of PET and CT/MRI to actually visualize a clinically proven primary tumor, PET generally had a higher sensitivity than other imaging studies. This is related to the fact that smaller or submucosal malignancies may be difficult to distinguish from adjacent tissues with anatomic imaging studies alone. For instance, in a recent study from Australia involving 40 patients with HNSCC (mostly tumors of the oral cavity), FDG-PET detected 35/40 primaries (88%), compared with CT, which only detected 18 of the 35 primaries imaged (51%). Of the 17 primaries not detected by CT, 11 were clearly visualized by FDG-PET. 13 
Nodal Staging
The second goal of PET imaging in primary staging is the assessment of the nodal status in the neck. The presence of nodal metastases is an independent prognostic factor for survival in patients with head and neck cancer, it decreases the overall survival by approximately one half. 14 The prognosis worsens additionally with the number of lymph nodes involved, 15 with extracapsular spread of nodal disease [16] [17] [18] and with metastases located in the lower neck. 19, 20 The presence and extent of nodal metastases may affect patient management. Early removal of neck nodal metastases also has prognostic implications. 21 Accurate nodal staging of the neck is therefore important.
The clinical neck examination and anatomic imaging studies suffer from a lack of sensitivity and specificity in assessing the extent of nodal disease (Table 2) . [22] [23] [24] [25] [26] [27] With CT and MRI lymph nodes are primarily characterized based on size criteria. Although other parameters, such as grouped location, central necrosis and contrast enhancement, can be used, CT and MRI frequently have false negative rates between 10% and 30%.
Numerous studies have compared the accuracy of anatomic imaging modalities and FDG-PET for the detection of nodal metastases in the neck. 13,24,27-32 A summary of findings is shown in Table 3 . In most studies PET had a higher sensitivity and specificity than CT, MRI, or ultrasound. However, because of the lack of anatomic information PET alone may not be accurate in determining the exact nodal station involved by metastases (eg, level II versus level III). It should also be noted that recently introduced superparamagnetic contrast agents, such as ferrum oxide particles, appear to increase the accuracy of MRI for nodal staging in the neck. 33, 34 Reasons for false-negative PET studies may include a small tumor burden in metastatic nodes, cystic degeneration of metastatic nodes only surrounded by a small rim of viable tumor tissue, low tracer uptake in the metastatic node, and imaging artifacts. Nodal metastases in close proximity to the primary tumor may not be detectable as separate hypermetabolic focus when the primary show very intense tracer uptake. 
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Assessment of Distant Metastases and Synchronous Second Primary Malignancies
Distant metastases are rare in patients with head and neck cancers, but the frequency increases with higher T-stage and size and number of tumor-involved lymph nodes. Patients with nodal metastases in the lower neck or supraclavicular region have a higher chance for distant metastases, too. In general, patients with HNSCC have a higher propensity for synchronous second primaries as compared with many other malignancies. For instance, in a smaller series evaluating the role of FDG imaging in head and neck cancer, Stokkel and coworkers 35 found a synchronous second primary in 12 of 68 patients in their series, although a technically inferior dual-head gamma camera was used. Five of these second primaries were also detected by clinical examination, chest radiograph or CT, so that the PET detection rate was really 7/68, or 10%.
In a recent prospective study of 33 patients with stage II-IV carcinoma of the oral cavity, oropharynx and larynx, FDG-PET detected distant metastases or synchronous second primary tumors in the aerodigestive tract in almost 30% of cases (7 distant metastases and 3 synchronous second primary tumors). 36 Based on our own experience a second primary or distant metastases outside the neck will be detected in 3-8% of cases, depending on the stage and location of the primary tumor. Indeed, this was also reported in a large retrospective analysis, unrelated to PET imaging, where the risk for synchronous second primary tumors also approached 8%. 37 Although the routine use of other staging modalities, such as bone scan, chest CT or abdominal ultrasound is not indicated because of the low yield of positive findings, 38,39 we recommend and routinely perform PET imaging from the skull base to the floor of the pelvis for appropriate N and M staging in patients with head and neck cancer. Both distant metastases and potential synchronous primaries in the aerodigestive tract are very likely to be hypermetabolic and therefore easily detectable by FDG-PET.
Practical approach and take-home message. FDG-PET has good sensitivity and specificity for the detection of primary tumors in the upper aerodigestive tract and a higher accuracy for nodal staging of the neck than any other imaging modality. Distant metastases or synchronous second primary tumors are occasionally detected; therefore, the imaged field of view should extend from the skull base to the floor of the pelvis.
Treatment Evaluation
Depending on the stage and location of the disease, treatment options in head and neck cancer include surgery, radiation therapy alone, or radiation therapy in combination with (concurrent) chemotherapy, possibly followed by surgery. If surgery is the primary treatment modality, this may be followed by radiation therapy, depending on the stage and aggressiveness of the primary tumor, status of surgical margins etc. With the latter approach, imaging studies during or immediately at the end of therapy are usually not necessary. In contrast, patients with locally advanced disease (stage III-IV) may undergo combined chemo-and radiation therapy with curative intent, which may be followed by salvage surgery in case of residual or recurrent disease. In addition, protocols consisting of chemo-and radiation therapy now are also used in some patients with the intent of organ preservation (larynx, tongue). It is in these groups of patients that early assessment of treatment response (or detection of residual disease) is of critical importance because prompt salvage surgery improves local control of the disease. CT and MRI rely on structural changes and are notoriously unreliable in this setting. Because of treatment related edema and inflammation, which may cause alteration of normal tissue planes and nonspecific enhancement after administration of intravenous contrast, these studies frequently can not assess the presence of residual disease with sufficient accuracy. Metabolic PET imaging contributes valuable information in this setting. It allows for the early detection of local and regional disease whose treatment will improve local disease control with the extrapolation that this will also improve survival or at least quality of life.
Chemotherapy Alone or Combined Chemo-and Radiation Therapy
A number of studies have shown that PET can monitor the response to chemo-or radiation therapy in patients with head and neck cancer and may differentiate responders from nonresponders; 40-45 metabolic changes during therapy appear to correlate with tumor growth rate. 46 Brun and coworkers 47 studied 47 patients with head and neck cancer undergoing radical radiation-or combined chemoradiation therapy. Almost two thirds of these patients had stage IV disease. FDG-PET was performed before and 1 to 3 weeks after the initiation of therapy (ie, during the course of treatment). PET data were analyzed using SUV and quantitative measurements (metabolic rate of glucose, MRGl). Patients with complete response had, on average, lower posttreatment SUV and MRGl than those without complete response, but there was considerable overlap. Interestingly, the pretreatment SUV was lower in patients who showed a complete response to therapy (median 8.0 versus 12.0). Posttreatment SUV was not different between responders and nonresponders (median 4.4 versus 7.7, P ϭ 0.07), but quantitative measurements showed lower glucose metabolism in responders as compared with nonresponders (MRGl median 14 versus 27 mol/min/ 100 g).
Goerres and coworkers 48 studied 26 patients with stage III-IV HNSCC, and PET was performed at 6 weeks after the end of combined chemo-and radiation therapy (median dose 70 Gy). PET correctly detected residual disease in 10 patients (38%) and correctly excluded residual disease in 14 patients; one patient each had a false-positive and false-negative study. Hence, the sensitivity and specificity were 91% and 93%, with an accuracy of 92% for the detection of residual disease, metastases or second primaries. Interestingly, in 2 patients the 6-week PET also revealed a second primary tumor or distant metastasis, which had not been detected at the time of initial staging.
In patients with locally advanced disease, chemotherapy or combined chemo-and radiation therapy are also used in the neoadjuvant setting. Neoadjuvant treatment is given to render locally advanced disease surgically resectable, to allow for organ preservation (for instance in patients with larynx cancer), to improve survival and reduce metastasis.
PET contributes valuable information in this setting. For instance, FDG-PET appeared to distinguish accurately between responders and nonresponders to neoadjuvant chemotherapy in an organ-conservation protocol. 45 All 27 patients enrolled had tissue biopsies taken before and after therapy. At the end of treatment 21 patients were found to be responders and 6 to be nonresponders. Using visual analysis and SUV, the study had a sensitivity of 90% and specificity of 83%. In another study in 15 patients undergoing neoadjuvant chemoradiation therapy, lesions with higher pretreatment SUV (Ͼ7) showed residual viable tumor cells after treatment in 3 of 8 cases, whereas all lesions with SUV Ͻ7 were treated successfully. 42 All 7 tumors with posttreatment SUV of Ͻ4 showed no viable cells on resection, whereas 3/7 tumors with posttreatment SUV Ͼ4 did show residual viable tumor cells. In another study in 23 patients the same authors separately analyzed the accuracy of various imaging modalities for the assessment of residual disease after neoadjuvant chemoradiation therapy: 44 FDG-PET was more accurate than MRI or CT in detecting residual disease (specificity 89% versus 41%, 59%) in the primary tumor following treatment, although no such difference was noted for nodal metastases.
Radiation Therapy Alone
Greven and coworkers have repeatedly investigated the role of FDG-PET in the assessment of response to radiation therapy. [49] [50] [51] One of their recent studies 51 evaluated 45 patients before and at 1, 4, 12 and 24 months after high-dose radiation therapy. Thirty-six patients were studied 1 month after radiation therapy. Of these, all six scans interpreted as positive for residual 184 SCHÖ DER AND YEUNG disease were true positive, whereas 7 of the 28 scans interpreted as negative were false negative, and residual tumor was found in 4/5 equivocal studies. Twenty-eight patients had PET performed at 4 months after radiation therapy. All 18 negative scans were true negative, 6/7 positive scans were true positive and residual cancer was found in 2/3 equivocal scans. The authors concluded that imaging at 4 mos after radiation therapy was more accurate than at 1 month. However, it needs to be emphasized that no imaging studies were acquired between 1 and 4 months. In our own experience a time interval of 6 to 8 weeks after treatment is usually sufficient to avoid most false positive and false negative findings. FDG-PET has the ability to detect patients with more aggressive disease before therapy and to differentiate between responders and nonresponders to (chemo-) radiation therapy. However, most studies suffer from limitations related to small sample size and the methods of data analysis (data dichotomized based on median SUV in study population, use of arbitrary cut-off values etc.). In addition, quantitative measurements of FDG utilization, as used in some of these studies, are not practical in a clinical routine setting. Larger, prospective studies in a well-defined setting are needed to determine the clinical value of PET in these patients conclusively.
Practical Approach and Take-Home Message
The treatment response to chemo-and radiation therapy can be monitored with FDG-PET. A negative PET scan obtained at least 6 weeks after the end of therapy excludes residual disease with high certainty. A positive scan obtained at least 6 weeks after end of therapy suggests residual disease, unless there are clinical signs of inflammation/infection to explain PET abnormalities. The clinical significance of PET changes during and immediately after the end of therapy is the subject of ongoing studies; these results should not be used in isolation to guide patient management decisions.
Recurrent Disease
The early detection of recurrent head and neck cancer is important in determining the ability to perform salvage surgery, which can improve the clinical outcome of these patients. For instance, patients with recurrent early stage HNSCC who undergo salvage surgery have a 70% 2-year relapse-free survival, whereas those with recurrent advanced stage disease HNSCC undergoing salvage surgery have a 22% 2-year RFS. 52 It is therefore critically important to detect potential recurrences early in the course of events. An imaging modality used for this purpose should have a high sensitivity for the detection of disease, but at the same time not yield too many false-positive findings.
CT and MRI, which rely on structural changes, are notoriously unreliable in this setting because of treatment related alterations of tissue planes, nonspecific contrast enhancement etc. 53, 54 However, the PET interpretation may also be complicated because postsurgical changes can involve distortions of the normal anatomy related to resection and surgical reconstruction, involving various soft tissue flaps, bone grafts, bone plates, surgical obturators etc. 55, 56 The role of FDG-PET for the detection of local recurrent head and neck cancer was initially investigated in a number of smaller, retrospective studies. 25, 50, [57] [58] [59] It is now clearly established that FDG-PET has a high sensitivity and specificity for the detection of recurrent disease in patients with head and neck cancer, regardless of the primary treatment modality used (surgery versus radiation therapy). 10,25,28,57,60-69 Results of larger, more recent PET studies are shown in Table 4 , and a patient example is shown in Fig 2. As a rule, clinically detectable recurrent disease is extremely unlikely in the setting of an entirely negative PET scan. FDG uptake, not related to tumor, can sometimes cause false positive (nontumor-related FDG uptake considered to represent tumor; see Fig 3) or false negative (tumor-related FDG uptake misinterpreted as normal variant, inflammation) interpretations. With adequate patient preparation, certain sources of nontumor-related FDG uptake can be eliminated or at least correctly identified (eg, laryngeal muscle uptake, radioactive saliva in the throat or vallecula epiglottica, nonspecific FDG uptake in brown fat tissue of the neck) but others cannot (treatment-related inflammation). Nevertheless, some false positive findings may be unavoidable. Accordingly, the sensitivity for the detection of recurrent head and neck cancer is consistently high, but specificity in the treated postsurgical area is lower than elsewhere in the neck or at remote sites, such as lung or bone, 68, 69 (see Table 4 ). Across all studies the negative predictive value is consistently high. Therefore, one can conclude that patients with suspected recurrence but negative PET scan do not require any further evaluation. In contrast, positive predictive value and specificity are somewhat lower for local recurrence at or near the site of the primary tumor, related to a number of false-positive findings. Nevertheless, if used in a clinical algorithm, a positive PET scan requires a biopsy; if this biopsy is negative for recurrent cancer and does not provide reasons for a false-positive PET scan (inflammation, infection, radiation necrosis etc.), close clinical follow-up and potential repeat biopsy may be required.
Recurrence Versus Treatment-Related Changes
Some studies specifically confirmed the ability of FDG-PET to distinguish between tumor recurrence and radiation therapy-induced changes. 50, 62, 63, 70 Teerhard and coworkers 63 studied 75 patients with laryngeal or oro-/hypopharyngeal cancer, using FDG and a dual-head gamma camera
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and visual image analysis. Local recurrence was eventually diagnosed in 37 patients. A negative FDG study correctly excluded recurrent disease in 24 patients, but missed it in 3 patients. A positive PET scan was less reliable, correctly identifying 34 cases of recurrence, but at the expense of 14 false-positive findings. Of note, the number of falsepositive findings decreased on subsequent PET scans. The smallest tumor detected was 4 mm. The authors therefore suggested an approach whereby a positive PET scan, because it indicates high risk for recurrence, should trigger biopsy. If the biopsy is negative, a follow-up PET scan should be obtained; if the intensity of FDG uptake declines with time no further study is needed. Otherwise, repeat biopsy is suggested. Conversely, a negative PET scan almost certainly excludes recurrent disease (NPV-89%). In this context it also interesting that in this study, 160 laryngoscopies under anesthesia with biopsy were necessary to detect local recurrence in 37 of the 75 patients, translating into a sensitivity of 51%-a truly poor performance for any diagnostic test. Unless there is strong clinical suspicion for recurrence, repeated biopsies should therefore be avoided as these are associated with a higher rate of complication in the irradiated tissue, in particular in the larynx.
Role of SUV Measurements
Although initial studies created much hope that quantitative or SUV analysis might be a suitable means for the detection of recurrent disease, 50,57 subsequent work proved that this is clearly not the case. For instance, Lapela and coworkers 65 reported a wide overlap in SUVs for disease recurrence (range, 2.1-36.9) versus nontumor-related FDG accumulation (range, 1.5-9.3). Several authors have used ROC analysis to determine the best cut-off for an SUV that distinguishes between recurrent disease and benign conditions; 64, 65, 68 for instance, Wong and coworkers 68 found that an SUV of 3.2 provided the best trade-of between sensitivity (92%) and specificity (70%), yielding an area under the curve of 0.88 Ϯ 0.02. These numbers may provide some guidance but may vary, for instance depending on the specific patient population and imaging protocol. Of note, there seems to be agreement, that interpretation of the PET study by an experienced PET reader provides the highest 
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accuracy. 64, 65, 68 Hence, SUV measurements should be used judiciously; they may aid in the interpretation but are not a surrogate for readers experience and should not be the sole criterion on which study interpretation rests.
PET for Surveillance of High-Risk Patients
All of the above studies were conducted in patients who were clinically suspected of having recurrent carcinoma. In contrast, Lowe and coworkers 67 performed routine PET imaging in 44 patients with stage II or IV head and neck cancer who were at higher risk for recurrence. During the first year of follow-up, PET was performed at 2 and 10 months, thereafter as considered necessary by the treating physician. All patients participated in an organ-preservation protocol that involved neoadjuvant chemotherapy, radiation therapy and surgical salvage (if needed). Thirty patients completed their treatment and were considered NED at the end of the protocol. Of these, 16 developed recurrent disease and 14 remained NED during the first year of f/u. PET had a sensitivity of 100% and specificity of 93% for identifying recurrences during that time period. Notably, 5/16 recurrences were detected by PET only, while the other recurrences were also identified by CT/MR or clinical examination. Early detection of recurrent disease is likely to improve the success rate for any secondary therapy, but it is nevertheless difficult to justify such a surveillance strategy without further supporting data. Moreover, PET studies for the sole purpose of surveillance are currently not reimbursed.
Practical Approach and Take-Home Message
FDG-PET is highly accurate in the detection of recurrent HNSCC. The interpreting nuclear medicine physician should be familiar with treatment-related changes that can cause false-positive studies. A negative PET scan excludes recurrence with high certainty; positive PET findings should be assessed further by biopsy, unless there is clear clinical recurrence. If the biopsy is negative, a follow-up PET scan is suggested 2 to 3 months later. If the SUV decreases, malignancy is unlikely and no further intervention is needed. If the SUV is unchanged or increases, repeat biopsy is suggested, unless there is another obvious explanation, such as infection, fistula or radionecrosis.
Prognostic Value of FDG-PET Imaging in Patients with Head and Neck Cancer
Several studies have shown that FDG-PET by itself can assess the aggressiveness and proliferation rate of HNSCC [71] [72] [73] and therefore correlates with patient prognosis, regardless of the treatment modality used. 43, 74, 75 In both untreated patients as well as patients with recurrent disease, the intensity of FDG uptake in the tumor appears to predict the ultimate outcome after therapy. 68, 69, 74, 75 In patients with recurrent disease, clinical PET interpretation and SUV are independent prognostic markers for relapse-free and overall survival 68, 69 However, there is currently no proof that the information derived from such studies should alter the patient management; whether a clinically established treatment approach should be changed or modified in individuals with poor prognosis based on PET findings should be investigated further as part of research protocols.
PET/CT in Head and Neck Cancer
PET/CT is a new imaging modality providing an almost simultaneous acquisition of anatomic and metabolic imaging data. This modality has been used increasingly for clinical oncologic imaging since 2001. Emerging data 
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SCHÖ DER AND YEUNG demonstrate that the combination of PET and CT in one image set improves the anatomic localization of PET abnormalities, decreases the number of equivocal PET interpretations, 76 and improves the diagnostic accuracy for staging of lung and colorectal cancer as compared with PET or CT alone. [77] [78] [79] With regard to head and neck cancer we have outlined above that PET alone is a highly valuable imaging technique in the primary staging and detection of recurrent disease. Unfortunately, many PET interpretations oftentimes suffer from the lack of anatomic information in PET images. This is particularly critical in the head and neck region because of close proximity of various anatomic structures and the high frequency of normal variants in FDG uptake in the head and neck. Accordingly, we have recently shown that in patients with head and neck cancer, PET/CT is a more accurate imaging modality than PET alone because PET/CT fusion imaging allows to establish a clear diagnosis (benign versus malignant) and localize abnormalities with high certainty (Fig 4) . In addition, the routine clinical application of this new modality also translates into improvements in patient management. 80 Therefore, we now use PET/CT as the standard imaging modality in patients with head and neck cancer.
THYROID CARCINOMA
Nuclear medicine has been one of the mainstays of management of thyroid disease. Since the early 1950s, the whole body scan (WBS) using tracer dose of iodine- 
(
131 I) has been widely used for detection of metastases of differentiated thyroid cancer (DTC). High dose 131 I has also been widely used for the ablation of thyroid remnant in the neck as well as therapy of metastatic diseases detected on the diagnostic WBS. The efficacy of this approach has been confirmed repeatedly in multiple large studies. [81] [82] [83] The management of thyroid cancer patients changed in the early 1970s with the clinical introduction of serial thyroglobulin measurements; this is now considered one of the most sensitive tests in the detection of metastatic DTC. 84 Indeed, a recent consensus report 85 proposed a surveillance guideline using only thyrotropin (TSH) stimulated thyroglobulin levels for low risk patients who have undergone total or near total thyroidectomy and 131 I ablation. Routine use of WBS in this group of patients is deemed not necessary. In contrast, WBS is still indicated for high-risk patients or patients with elevated serum thyroglobulin. Controversy exists regarding the management of patients with high serum thyroglobulin and negative WBS. Empirical treatment with a therapeutic dose of 131 I will result in a positive post therapy scan and a decline in the serum thyroglobulin level in the majority of these patients, 86, 87 although it remains to be seen if this strategy results in longer survival. 88 FDG-PET can localize metastatic disease in a number of these patients and thereby guide further management.
PET-FDG in Differentiated Thyroid Cancer
Early studies found a low sensitivity of FDG-PET in the detection of metastases. 89 However, others reported a sensitivity of 50% in 58 unselected patients with DTC, thyroidectomy and prior radioactive iodine (RAI) ablation, 90 and in a large multicenter study with un-selected patients, the sensitivity of FDG-PET for localizing metastatic disease in patients with DTC was 75%. 91 As early as 1987, Joensuu and coworkers 89 noticed metabolic heterogeneity between metastases of DTC in a study showing tumors that accumulated only FDG, only 131 I, or both. This was confirmed in more recent studies. 92, 93 It became apparent that there were patients with positive WBS but negative FDG-PET and vice versa. Even in the same patient the accumulation of FDG and iodine may differ between different metastatic sites ( Fig  5) . Feine and coworkers 94 coined the term "flip flop" in describing the alternating pattern of either 131 I or FDG uptake in thyroid cancer metastases.
The utility of FDG-PET scan in patients with elevated serum thyroglobulin and negative WBS was confirmed in several studies, [95] [96] [97] [98] [99] and the sensitivity of FDG-PET in detecting metastases in these cases ranges from 71% to 94%. For instance, Wang and coworkers reported FDG-PET detected metastatic disease in 12/17 patients (71%) with elevated thyroglobulin and negative WBS. 97 In this series PET was also positive in 5/16 patients with low 
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SCHÖ DER AND YEUNG thyroglobulin but high clinical suspicion, although only 2 findings were true positive. Helal and coworkers prospectively looked at 37 patients with DTC who had undergone resection, RAI ablation and presented with elevated thyroglobulin levels but negative WBS. FDG-PET scan was positive in 28 patients (76%), including 19 of 27 patients with no previously detected metastases by conventional imaging. 98 In a prospective study of 24 patients with DTC, negative WBS and elevated thyroglobulin levels, Frillings and coworkers reported a sensitivity of 94.6% in the detection of metastases, with specificity of 25%. PET results changed surgical tactics in 9/24 patients. 99 Schluter studied 118 PET scans in 64 thyroid cancer patients with elevated serum thyroglobulin (n ϭ 48) or clinical suspicion of metastases (n ϭ 16) and negative WBS. 100 The positive predictive value of FDG-PET scan was 83% (34/41) whereas the negative predictive value was 25% (5/20). Treatment was directly changed in 19/24 patients with true positive PET studies (30% of the entire cohort). They also pointed out that true positive FDG-PET findings were correlated positively with increasing serum thyroglobulin levels. In addition to lesion detectability, there is also evidence that FDG-PET is an independent prognostic indicator in thyroid cancer. 93, 94, 101, 102 In a study by Wang and coworkers., which included 125 patients with negative WBS, positive FDG-PET, elevated thyroglobulin with a clinical follow-up of up to 41 months, multivariate analysis demonstrated that the single strongest predictor of survival was the volume of FDG-avid disease. 101 More recently the same group showed strong inverse correlation between the SUV for FDG uptake in metastatic lesions and survival in thyroid cancer patients. 102 The WBS with 131 I is more sensitive for localizing recurrent or metastatic disease when TSH levels are elevated, either due to withdrawal of thyroid hormone replacement therapy or due to administration of exogenous TSH. However, there is no consensus regarding whether an FDG-PET should also be performed under TSH stimulation, although it has been shown that the expression of glucose transporters and glucose uptake in (cultured) thyroid cells is increased with TSH stimulation. 103, 104 Earlier studies employed different patient preparations. 90, 92, 97 One study suggested that the state of TSH stimulation did not affect results 97 and one multicenter study even showed lower sensitivity of FDG-PET when imaging was performed during TSH stimulation (67% as compared with 91% during thyroid hormone therapy). However, more recent studies seem to suggest that sensitivity or at least the clarity of findings improves with TSH stimulation. For instance, Moog and coworkers studied 10 patients prospectively with FDG-PET both under TSH suppression as well as in the hypothyroid, TSH stimulated state. 105 They found an average increase of 63% in the tumor to background ratio after TSH stimulation for 15 of the 17 lesions that showed FDG uptake (decreased background activity and increased tumor uptake). In one patient, a lesion was seen in the thyroid bed only under TSH stimulation. Petrich and coworkers studied 30 patients with negative WBS and elevated thyroglobulin levels and compared FDG-PET images obtained under TSH suppression with those obtained under stimulation with recombinant human TSH (rhTSH). 106 They found more "tumor-like lesions" (78 versus 22) in more patients (19 versus 9) when patients had received rhTSH. Tumor to background ratios (2.54 versus 5.51) and SUV (2.77 versus 2.05) were also higher with TSH stimulation.
In conclusion, FDG-PET is useful in patients with clinical evidence of metastatic DTC but negative WBS. It serves to identify sites of disease, providing valuable information in directing further investigation and management. If a solitary metastasis is confirmed with CT or MRI, surgical resection with curative intent is indicated. Nonresectable regional disease can be treated with external beam irradiation, while widespread disease may be amenable to experimental chemotherapy. Identification of distant metastases may also spare the patient the morbidity of aggressive local curative maneuvers.
Hü rthle Cell Carcinoma
Hürthle cell cancer is a histologic subtype of DTC that is clinically more aggressive. The tumor frequently shows little or no iodine uptake, but can be identified with FDG-PET: a meta-analysis of two studies and 35 patients showed a sensitivity of 92% and specificity of 82%. 107 A sensitivity of 92% (12/13 patients) was also reported in another recent study. 108 More importantly, in 7 of these 13 patients PET showed disease not identified by other imaging methods.
Anaplastic Thyroid Cancer
This is an extremely aggressive tumor and imaging is not required for staging, since all patients are classified as stage IV at diagnosis. As a result FDG-PET scan in anaplastic thyroid cancer has not been studied systemically. However, in our own experience and in some case reports 89 this malignancy usually shows intense FDG uptake, and in selected cases FDG-PET may be helpful in directing treatment and evaluating the efficacy of therapy (Fig 6) .
Medullary Thyroid Cancer
Medullary thyroid cancer is a rare calcitonin secreting tumor originating from the parafollicular C cells. The primary treatment modality is surgical resection. A PET study may be requested in patients with high serum calcitonin level after surgery. The number of patients studied for this purpose is limited, but it appears that FDG-PET can identify metastatic disease more fre-
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quently than other imaging studies. A study of 20 patients reported a sensitivity of 76%, 109 and in a large multicenter study the sensitivity of 78% among 55 patients in whom histologic confirmation was obtained. 110 Interestingly, there was no correlation between the calcitonin level and the probability of lesion detection. Indeed it has been suggested that more undifferentiated cancer, which secretes less calcitonin, may show higher FDG uptake, analogous to the situation in DTC. Novel, more specific PET tracers, such as 6-18 F-fluorodopamine 111 or 18 F-DOPA 112 may be more appropriate for the detection of recurrent or metastatic medullary thyroid cancer.
Thyroid Incidentaloma
The normal thyroid gland shows low grade FDG uptake or is usually not visualized on the whole-body FDG-PET scan. Occasionally, diffusely or focally increased FDG uptake is seen as an incidental finding in the thyroid gland. In a large series of patients it was proven that diffuse thyroid FDG uptake is usually an indicator of chronic thyroiditis. 113 In contrast, focal FDG activity in the thyroid gland has been associated with malignancy. 114, 115 In a retrospective review of over four thousand patients, Cohen and coworkers found incidental diffuse thyroid FDG uptake in 31 patients (0.69%) and focal uptake in 71 patients (1.57%). 116 Fourteen of the patients with focal uptake had thyroid biopsy: 7 had thyroid cancer, and the other 7 had benign pathology (nodular or lymphoid hyperplasia and atypical cell of indeterminate origin). Patients with malignant lesions had a significantly higher SUV (6.92 Ϯ 1.54), compared with those with benign lesions (3.37 Ϯ 0.21, P ϭ 0.04).
The one patient with diffuse uptake and biopsy had Hashimoto's thyroiditis. Among 1330 subjects (999 cancer patients, 331 healthy subjects undergoing cancer screening) Kang and coworkers 117 noted incidental diffuse thyroid FDG uptake in 8 (0.6%) and focal uptake in 21 individuals (1.58%). Four of the 15 focal incidentalomas (27%) whose histological diagnoses were available showed papillary carcinoma. Hence the risk of cancer was lower than in previous studies, but still large enough to warrant further evaluation of such findings. Again, the SUV in malignant lesions was higher than in benign lesions (16.5 Ϯ 4.7 versus 6.5 Ϯ 3.8). Of note, the prevalence of thyroid incidentaloma was similar for cancer patients and healthy individuals. All eight patients with diffuse FDG uptake in the thyroid glands had clinical signs and symptoms of thyroiditis.
In summary, diffusely increased thyroid FDG uptake is most likely benign, usually due to chronic thyroiditis, whereas focal FDG uptake in the thyroid gland has a significant risk of being malignant (27-50%); histologic diagnosis should therefore be obtained for focal lesions if the nature of the thyroid disease changes management.
PET Imaging with 124 Iodine
124 Iodine has a half-life of 4.2 days and a relatively complex decay scheme, with 22% of the disintegrations producing positrons of relatively high energies (1532 keV and 2135 keV), as well as a number of high energy gamma and X-rays, with energy as high as 1691 keV. Despite the high abundance of high energy gamma photons images of satisfactory quality can be acquired and quantitation of tracer uptake can be performed with only minor degradation in image resolution and quanti- 
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SCHÖ DER AND YEUNG tation. 118 Indeed, PET with 124 I provides images of higher spatial resolution and lesion contrast compared with either planar scintigraphy or SPECT using 131 I, resulting in better lesion detection. The recent introduction of PET/CT has improved the localization of focal 124 I accumulation. 119 This is invaluable in 124 I imaging where most normal structures show little uptake, making localization of lesions difficult, if not impossible. The main purpose of 124 I PET imaging is lesion dosimetry, which would provide a more scientific basis for determining the necessary activity for treatment with 131 Iodine. 120, 121 However, because of problems with radiopharmaceutical availability and cost, it is unlikely that iodine-124 PET dosimetry would be routinely used clinically.
CONCLUSION
PET imaging with FDG has become standard clinical practice in patients with head and neck cancer. It contributes valuable information in the primary staging of the disease, in particular in nodal staging of the neck and in the assessment for distant metastases or synchronous second primary malignancies. FDG-PET is very accurate in the detection of recurrent disease and should be used as the imaging modality of choice in patients at high risk for or with clinically suspected recurrence. PET can be used for the treatment evaluation in patients undergoing chemotherapy or combined chemo-and radiation therapy. Imaging at least 6 weeks after the end of therapy appears more accurate. Because the intensity of tracer uptake in tumor tissue correlates with tumor proliferation and aggressiveness, FDG-PET provides independent prognostic information in both patients with primary and recurrent HNSCC with regard to relapsefree and overall survival. PET imaging with various radiolabeled amino acids does not appear to be superior to FDG imaging in head and neck cancer. The recent introduction of PET/CT fusion imaging into clinical practice has improved the accuracy of PET interpretation in patients with head and neck cancer. Due to shorter imaging time, greater certainty and higher accuracy in image interpretation and a positive effect on patient management, all patients with head and neck cancer in our institution are now imaged exclusively by PET/CT.
In patients with evidence of recurrent or metastatic thyroid carcinoma but negative WBS, FDG-PET shows metastatic disease in up to 90% of cases. In patients with medullary thyroid cancer with elevated calcitonin levels following thyroidectomy, FDG-PET has a sensitivity of 70-75% for localizing metastatic disease. Incidentally noted intense focal FDG uptake in the thyroid gland can be related to thyroid cancer in 25 to 50% of cases and should therefore be evaluated further if a proven malignancy would cause a change in patient management. 
